CSP Exam Test Specialty Pharmacy
UPDATED ACTUAL Questions and
CORRECT Answers
PDC calculation - CORRECT ANSWER - (# of unique days with supply / number of days in
a period) x 100
Jak inhibitor - CORRECT ANSWER - Xeljanz (tofacitinib)
Cholesterol-elevating medication - CORRECT ANSWER - Actemra (toclizumab)
Shingles vaccine safe with TNF inhibitors - CORRECT ANSWER - Shingrix
Neutropenia risk - CORRECT ANSWER - Taltz (ixekizumab)
Psoriasis medication without tuberculosis screening - CORRECT ANSWER - Otezla
(apremilast)
Standard starting dose for Taltz (ixekizumab) in psoriatic arthritis - CORRECT ANSWER -
160mg subcutaneously once, followed by 80mg subcutaneously every 4 weeks
Medication recommendation for severe dermatitis in a 45 y/o patient - CORRECT
ANSWER - Dupixent (dupilumab)
Starting dose for Stelara (ustekinumab) in psoriasis - CORRECT ANSWER - Inject 45 mg
subcutaneously at weeks 0 and 4, followed by 45 mg every 12 weeks
Oral oncology medication without caution in hepatic impairment - CORRECT ANSWER -
Ibrance (palbociclib)
UPDATED ACTUAL Questions and
CORRECT Answers
PDC calculation - CORRECT ANSWER - (# of unique days with supply / number of days in
a period) x 100
Jak inhibitor - CORRECT ANSWER - Xeljanz (tofacitinib)
Cholesterol-elevating medication - CORRECT ANSWER - Actemra (toclizumab)
Shingles vaccine safe with TNF inhibitors - CORRECT ANSWER - Shingrix
Neutropenia risk - CORRECT ANSWER - Taltz (ixekizumab)
Psoriasis medication without tuberculosis screening - CORRECT ANSWER - Otezla
(apremilast)
Standard starting dose for Taltz (ixekizumab) in psoriatic arthritis - CORRECT ANSWER -
160mg subcutaneously once, followed by 80mg subcutaneously every 4 weeks
Medication recommendation for severe dermatitis in a 45 y/o patient - CORRECT
ANSWER - Dupixent (dupilumab)
Starting dose for Stelara (ustekinumab) in psoriasis - CORRECT ANSWER - Inject 45 mg
subcutaneously at weeks 0 and 4, followed by 45 mg every 12 weeks
Oral oncology medication without caution in hepatic impairment - CORRECT ANSWER -
Ibrance (palbociclib)
